Home » Stocks » AMPH

Amphastar Pharmaceuticals, Inc. (AMPH)

Stock Price: $18.13 USD 0.31 (1.74%)
Updated December 3, 10:57 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 861.25M
Revenue (ttm) 337.31M
Net Income (ttm) 6.65M
Shares Out 47.50M
EPS (ttm) 0.14
PE Ratio 129.50
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $18.13
Previous Close $17.82
Change ($) 0.31
Change (%) 1.74%
Day's Open 17.81
Day's Range 17.62 - 18.13
Day's Volume 56,026
52-Week Range 12.66 - 22.46

More Stats

Market Cap 861.25M
Enterprise Value 824.64M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 47.50M
Float n/a
EPS (basic) 0.15
EPS (diluted) 0.14
FCF / Share 0.28
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.77%
FCF Yield 1.52%
Payout Ratio n/a
Shares Short 2.69M
Short Ratio 17.16
Short % of Float n/a
Beta 1.03
PE Ratio 129.50
Forward PE n/a
P/FCF Ratio 65.80
PS Ratio 2.55
PB Ratio 2.12
Revenue 337.31M
Operating Income 7.83M
Net Income 6.65M
Free Cash Flow 13.09M
Net Cash 36.61M
Net Cash / Share 0.77
Gross Margin 39.11%
Operating Margin 2.32%
Profit Margin 2.00%
FCF Margin 3.88%
ROA 1.33%
ROE 1.73%
ROIC 2.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 3
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$22.20*
(22.45% upside)
Low
20.0
Current: $18.13
High
24.0
Target: 22.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue322295240255252210230204118
Revenue Growth9.4%22.69%-5.87%1.45%19.51%-8.37%12.41%72.63%-
Gross Profit13210790.5110477.3551.2686.9690.3028.10
Operating Income-0.04-8.62-1.2715.38-6.90-17.9817.4925.40-33.55
Net Income48.94-5.743.659.82-2.79-10.7011.8618.097.75
Shares Outstanding46.9846.4046.1145.3844.9641.9638.7138.5838.51
Earnings Per Share0.98-0.120.080.21-0.06-0.250.310.460.20
EPS Growth---61.9%----32.61%130%-
Operating Cash Flow41.7638.1939.2138.5610.6821.0531.04-1.6519.10
Capital Expenditures-41.56-46.56-35.10-21.38-16.00-20.50-18.30-23.66-10.68
Free Cash Flow0.21-8.374.1117.18-5.320.5512.74-25.318.42
Cash & Equivalents89.5293.3272.3874.2767.3669.3254.9152.10-
Total Debt66.6350.2147.1637.7241.1043.7032.1738.00-
Net Cash / Debt22.8943.1125.2336.5526.2625.6222.7414.10-
Assets587514451428390389339317-
Liabilities15914911798.4894.6310887.2084.04-
Book Value381332334329296282252233-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Amphastar Pharmaceuticals, Inc.
Country United States
Employees 2,027
CEO Jack Zhang

Stock Information

Ticker Symbol AMPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Unique Identifier NASDAQ: AMPH
IPO Date June 25, 2014

Description

Amphastar Pharmaceuticals, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; lidocaine jelly, a local anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection for newborn babies; atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; morphine injection; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as recombinant human insulin API (active pharmaceutical ingredients) and porcine insulin API. Further, the company has a pipeline of 20 product candidates in various stages of development for various indications. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.